614 Results
Sort By:
Published on May 22, 2024
Researchers at Washington University School of Medicine have found in a mouse study that a strain of the gut bacteria Ruminococcus gnavus can help enhance the effectiveness of cancer immunotherapy. The research, published in Science, points to the potential of using R. gnavus as a probiotic agent to improve the…
Published on February 7, 2024
A new study uncovers why natural killer (NK) cells stop actively attacking tumor cells once they infiltrate cancers and possibly offers a way to boost their activity. The researchers, from the University of Birmingham and the University of Cambridge, found evidence of why NK cells adopt a dormant state when…
Published on August 23, 2023
Etcembly, a U.K. biotech, has developed a new immunotherapy to target hard-to-treat cancers using generative artificial intelligence (AI) similar to that used to create ChatGPT. According to the company, this is the first time a candidate immunotherapy has been designed by generative AI. The new therapeutic candidate is a bispecific…
Published on July 20, 2023
GDF-15’s role in resistance to cancer immunotherapy was reinforced in a Nature Communications study published today. The researchers demonstrated that GDF-15 blocks LFA-1-dependent T cell recruitment into the tumor microenvironment, a prerequisite for responses to anti-PD-1/-L1 treatment and other immunotherapeutic strategies. This, the authors say, is the first paper to…
Published on April 12, 2023
Easily accessible information from hematoxylin and eosin (H&E)-stained tumor tissue on microscopy slides can predict which patients with metastatic clear cell renal cell carcinoma (mccRCC) are most likely to respond to immunotherapy, with the prediction further refined by adding PBRM1 mutation status, research suggests. The findings, from a retrospective study…
Published on April 4, 2023
Originally Aired: April 6, 2023Time: 11:00 am PT, 2:00 pm ET, 20:00 CET VIEW NOW Immune checkpoint inhibition with monoclonal antibodies targeting PD-1 and PD-L1 has revolutionized the care of patients with advanced cancer, with approvals in multiple solid tumor types and pan-tumor indications. However, current pan-tumor biomarkers do not identify most patients…
Published on December 7, 2022
In a reversal to accepted theories, scientists have discovered the adding radiation to immunotherapy does not boost the immune system. It’s actually the reverse. Yet, in several cancers, the combination together shows improved treatment responses over either treatment alone. The reason may have more to do with the tumor’s aneuploidy…
Published on December 7, 2022
Cancer patients’ response to immunotherapy may be predictable in part based on their levels of CD8+ T-cell infiltration, according to a new study. Such drugs are one of the world’s highest selling classes, estimated to have netted over $31B in 2021 and expected to bring almost $150M by 2030. But…
Published on June 8, 2022
Libraries of immune cells displaying diverse repertoires of chimeric antigen receptors (CARs) have been developed that can recognize non-self antigens and display antigen-dependent clonal expansion, with the expanded population of tumor-specific effector cells leading to long-lasting antitumor responses in mouse models of epithelial tumors. Over the past decade, substantial progress…
Published on April 18, 2022
Researchers in the Pelotonia Institute for Immuno-Oncology (PIIO) at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) observed the differences in intratumoral immune responses between male and female cancers of non-reproductive origin. The new study is published in…
Published on November 29, 2021
A review of patient data by researchers heading by scientists at MD Anderson Cancer Center showed that for some tumor types, taking H1-antihistamines in addition to receiving immunotherapy was significantly associated with improved overall survival. A preclinical study in rodents demonstrated that the histamine receptor H1 (HRH1) acts in tumor-associated…
Published on November 12, 2021
Stanford researchers have developed a new synthetic molecule, called PIP-CpG, that combines a tumor-targeting agent with a molecule that triggers immune activation. This treatment, can be administered intravenously and can make its way to multiple tumor sites, where it recruits immune cells against cancer. Three doses of this new immunotherapy…
Published on October 29, 2021
Immunotherapy is a common treatment for clear cell renal cell carcinoma (ccRCC), yet there are no tools to discern whether the treatment will be effective in individual patients. Now, researchers at the Francis Crick Institute, the Royal Marsden NHS Foundation Trust, and University College London (UCL) have published findings in…
Published on April 13, 2021
A study led by researchers at Massachusetts General Hospital reveals that factors such as age, combination of therapy and specific cancer type can influence the risk of severe adverse events in cancer patients prescribed immune checkpoint inhibitor immunotherapy. “Understanding the risk factors for predicting high-grade toxicities will help in appropriately…
Published on February 3, 2021
A method for rapid testing large numbers of potential immunotherapy drugs against live tumor cells for accurate and easily analyzable data, has been designed by researchers from the Los Angeles-based Terasaki Institute for Biomedical Innovation (TIBI). The team began by culturing spherical aggregates of breast cancer cells in a custom-fabricated,…